Vanguard Group Inc Infinity Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.14 - $0.24 $1,822 - $3,124	-13,017 Reduced 0.33%	3,981,857 $836,000
Q1 2023 May 15, 2023	SELL	$0.16 - $0.74 $211,008 - $975,915	-1,318,805 Reduced 24.82%	3,994,874 $639,000
Q4 2022 Feb 10, 2023	BUY	$0.46 - $1.21 $915 - $2,407	1,990 Added 0.04%	5,313,679 $2.98 Million
Q3 2022 Nov 14, 2022	BUY	$0.59 - $1.7 $24,056 - $69,314	40,773 Added 0.77%	5,311,689 $6.32 Million
Q2 2022 Aug 12, 2022	SELL	$0.49 - $1.2 $252,042 - $617,246	-514,372 Reduced 8.89%	5,270,916 $3.33 Million
Q1 2022 May 13, 2022	BUY	$0.85 - $2.4 $1,576 - $4,452	1,855 Added 0.03%	5,785,288 $6.6 Million
Q4 2021 Feb 14, 2022	BUY	$1.86 - $3.36 $419,009 - $756,920	225,274 Added 4.05%	5,783,433 $13 Million
Q3 2021 Nov 12, 2021	BUY	$1.52 - $3.82 $1.79 Million - $4.49 Million	1,175,354 Added 26.82%	5,558,159 $19 Million
Q2 2021 Aug 13, 2021	BUY	$2.66 - $3.47 $11.7 Million - $15.2 Million	4,382,805 New	4,382,805 $13.1 Million

1.26M

Ticker INFI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 89,277,904
Description
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of met...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.